Recent Updates
Recently added Catalysts

Centessa Pharmaceuticals plc

CNTA
Richly ValuedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$40.5
▲ 0 · 0%

Last traded Jun 23, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CNTA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $10.9552W HIGH $40.26
Volume
11.33 M
Value Traded
33.49 M
Short % Float
1.47%
+0.38%Week
+0.56%1 Month
+59.32%3 Month
+43.35%6 Month
+96.3%5 Year
+96.3%All Time

Cash Data

Unlock CNTA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
6.15 B
EPS (TTM)
-1.77
P/E Ratio
-
Ent. Value
5.99 B
Total Shares
154.73 M
Float Shares
109.31 M
Insiders
29.35%
Institutions
70.86%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every CNTA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CNTA Catalyst Timeline

Dated clinical, regulatory and corporate events for Centessa Pharmaceuticals plc

Unlock the full CNTA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CNTA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-31ORX142 Phase 1 data readout Phase 1
Unlock 5 more CNTA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C41 / 100
Pipeline Score
$612M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.1x
rNPV / MCap
Centessa Pharmaceuticals plc carries a moderate pipeline score (41/100), with $993M risk-adjusted pipeline value, led by SerpinPC in Hemophilia a (Phase 1).
Showing 1 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SerpinPC Small moleculeCompletedNCT04073498Hemophilia aPhase 1 COMPLETED 39Sep 26, 2024
Unlock the CNTA pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CNTA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
ORX750 NT1, NT2, and IHPhase 2a2025-11-05a total of 55 participants with NT1, NT2 and IH who completed dosing with ORX750 in the 2-week crossover cohortsRead MoreCentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist ProgramRead More
Scroll for more · summaries link to the source press release
Unlock every CNTA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CNTA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Medicxi Ventures Management (Jersey) Ltd10% OwnerSell -4,398,519 $0.00 06/24/2026
Unlock the full CNTA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in CNTA

Fund % of Portfolio Current MV Shares Owned Activity
Avoro Capital Advisors LLC 4.5 % (25 %) 454.02 M 11.43 M -21.47% ( -3.13 M)
Unlock every fund holding CNTA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CNTA
Shares held by hedge funds each quarter, and who bought or sold.

CNTA Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CNTA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CNTA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CNTA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CNTA ranks across every disease it competes in

Competitive Position is a premium feature
See how CNTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CNTA News

About Centessa Pharmaceuticals plc

Cheshire, X0 129 employees centessa.com
Headquarters3RD FLOOR, ALTRINCHAM, CHESHIRE, X0, WA14 2DT
BIOPHARMAWATCH ELITE PLUS
Trade the next CNTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime